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Questions 
 P e r s i s t  
Environmental Factors 
  in Autoimmune Disease
A
fter his first child was born, 
black and blue marks started 
showing up on Stanley Fin-
ger’s body. Jolted awake most nights 
by his crying infant, Finger would 
stumble half asleep toward her room, 
bumping into walls and furniture 
in the dark. “My wife and I would 
joke about it,” says Finger, a chemical 
engineer from Bluffton, South Caro-
lina. But during a routine checkup, 
Finger learned his easy bruising was 
caused by a precipitous drop in blood 
platelets. The body relies on these 
cell fragments for clotting, and Fin-
ger’s platelet count had dropped to 
nearly a third its normal value. After 
ruling out cancer and other illnesses, 
Finger’s doctor eventually arrived at a 
diagnosis: immune thrombocytopenia 
purpura (ITP). 
ITP is an autoimmune disease, 
a condition that occurs when the 
immune system attacks the body’s 
own cells and tissues. When Finger 
was diagnosed in 1974, autoimmune 
illnesses weren’t yet perceived as the 
public health menaces they’re often 
seen as today. But according to Fred 
Miller, director of the Environmental 
Autoimmunity Group at the Nation-
al Institute of Environmental Health 
Sciences, autoimmune diseases are now 
recognized as among the leading causes 
of death among young and middle-
aged women in the United States. 
What’s more, prevalence rates 
for some of these illnesses are rising 
for what Miller says must largely be 
environmental reasons. “Our gene 
sequences aren’t changing fast enough 
to account for the increases,” Miller
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says. “Yet our environment is—we’ve got 
80,000 chemicals approved for use in com-
merce, but we know very little about their 
immune effects. Our lifestyles are also dif-
ferent than they were a few decades ago, and 
we’re eating more processed food.” Should 
prevalence rates for heart disease and cancer 
continue their decline, Miller says, auto-
immune diseases could become some of the 
costliest and most burdensome illnesses in 
the United States. 
Sprawling Family of Illnesses
Until recently, scientists didn’t think of 
autoimmune illnesses as a group of related 
conditions.  Instead,  each  illness  was 
viewed as a unique and usually rare afflic-
tion. ITP, for instance, strikes barely 10 
people of every 100,000
1 (by comparison, 
the National Organization for Rare Dis-
orders defines rare illnesses as those occur-
ring in at most 250 people per 100,000 
in the population). And since no one had 
tallied auto  immune diseases under a sin-
gle umbrella, their cumulative impact on 
health and society wasn’t known. 
That troubled Noel Rose, an immunolo-
gist and professor at The Johns Hopkins 
University, who was convinced that medical 
science wasn’t giving enough thought to what 
autoimmune diseases share in common. So 
in the mid-1990s, Rose began doing what 
no one else had done. Along with a small 
group of colleagues, he combed through 
published journal articles and other epide-
miologic sources in an attempt to calculate 
how many people were afflicted with each 
of 24 auto  immune conditions, including 
multiple sclerosis, rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), and 
type 1 diabetes mellitus. 
Using 1996 population projections from 
the U.S. Census Bureau, Rose ultimately cal-
culated these conditions, as a group, affected 
up to 1 in every 31 Americans—more than 
8.5 million people at that time.
2 “That was 
remarkable,” Rose says. “Until then, no one 
had realized that autoimmune diseases are so 
common.”
According to current estimates by the 
National Institutes of Health, as many as 
23.5 million Americans may be afflicted 
with at least one autoimmune condition.
3 
But Rose says that number doesn’t account 
for 2010 U.S. Census data, and moreover, 
it’s drawn from the 24 autoimmune dis-
eases considered in Rose’s assessment, when 
the actual number of these illnesses ranges 
from 80 to as many as 120.
4 The actual size 
of the affected population in the United 
States could be as high as 50 million people,
5 
according to the American Autoimmune 
Related Diseases Association (AARDA), an 
advocacy group in East Detroit. 
Autoimmune diseases tend to cluster 
among family members. Finger’s first child, 
for instance, has autoimmune hepatitis, while 
her sister has type 1 diabetes. However, even 
though identical twins have the same genetic 
susceptibility to inherited illness, Rose says 
it’s possible only one will develop an autoim-
mune condition, suggesting the involvement 
of environmental triggers. 
Scientists define those triggers broadly: 
chemicals, infectious agents, stress, hor-
mones, drugs, diet, weight gain, behavior, 
and more have all been cited as etiological 
factors. Rose acknowledges that changes 
in diagnosis might account for some of the 
increase. “That’s hard to rule out because 
there’s a lot more clinical awareness of these 
diseases now than there used to be,” he says. 
“But there are also some very good stud-
ies that show real increases, particularly for 
type 1 diabetes.”
6,7 Given that type 1 diabetes 
has been well characterized for decades, this 
offers compelling evidence to date that rising 
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Environmental agents
Genomes
SLE
Systemic sclerosis
Myositis
Vasculitis
RA
Gene–Environment Interactions and  
Autoimmune Disease: One Hypothesis
In the elemental disorder hypothesis, autoimmune diseases are viewed as collections 
of many individual phenotypes, each defined by a unique set of symptoms, signs, 
and  laboratory  findings.  This  figure  uses  the  example  of  systemic  rheumatic 
diseases,  a  subset  of  autoimmune  diseases,  to  conceptualize  how  a  variety  of 
disease phenotypes may result from different gene–environment interactions. 
Each  sphere  represents  a  disease  phenotype,  each  square  represents  an 
individual’s  genome,  and  each  hexagon  represents  a  particular  environ  mental 
exposure. In this hypothesis, some combinations of genomes and environ  mental 
exposures lead to certain disease phenotypes, whereas other combinations might 
not. In still other cases, either an environ  mental factor or a genome may confer 
protection against developing disease, indicated here by an X.
RA = rheumatoid arthritis; SLE = systemic lupus erythematosus.
Source: Gourley M, Miller FW. Mechanisms of disease: environmental factors in the pathogenesis 
of rheumatic disease. Nat Clin Pract Rheumatol 3(3):172–180 (2007); doi:10.1038/ncprheum0435. 
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incidence is not simply an illusion based on 
better diagnosis.
Jill Norris, a professor of epidemiology 
at the Colorado School of Public Health, 
adds that the prevalence of celiac disease—an 
autoimmune affliction of the small intestine 
triggered by exposure to gluten, a protein 
found in wheat, barley, and rye—also appears 
to be rising dramatically in the United 
States.
8 “W e’ re probably seeing a mix of 
different trends,” Norris says. Where some 
autoimmune diseases are increasing, others 
are declining—for instance, the prevalence 
of RA appears to be falling in the population, 
she says. “And for most others,” she adds, “we 
don’t know, mainly because we don’t have the 
proper registries for tracking them.” 
Autoimmune Complexity 
Revealed
Scientists split autoimmune diseases into 
two general categories: organ-specific vari-
eties (such as type 1 diabetes, which is 
an immune attack on insulin-producing 
cells in the pancreas) and systemic vari-
eties (such as SLE, which occurs when 
the immune system turns against multiple 
organs and tissues throughout the body). 
Clinical outcomes vary by illness, rang-
ing from bleeding disorders in ITP, to an 
inability to process glucose in type 1 diabe-
tes, to joint pain and inflammation in RA. 
Given that autoimmune diseases are 
often rare and may not be easily diagnosed 
with blood tests, imaging, and other stan-
dard tests, clinicians who aren’t familiar 
with these illnesses can find them perplex-
ing. It’s not unusual for truly sick patients to 
be dismissed by medical professionals as lazy 
or neurotic, says Finger, now chairman of 
the AARDA board of directors. “It can take 
years to diagnose some of these conditions,” 
he says. “Patients can be shunted from one 
specialist to another. Even as late as 2000, 
mental health professionals were often the 
first to make a correct diagnosis.” 
All autoimmune diseases occur when 
the body’s immune system turns against 
itself. But according to Kathleen Gilbert, an 
immunologist and professor at the Univer-
sity of Arkansas for Medical Sciences, that’s 
about the only thing we know for sure about 
them. Scientists have barely scratched the 
surface when it comes to knowing what trig-
gers an autoimmune illness, she says. 
The field is replete with competing theo-
ries and biological mechanisms, but it lacks 
a unifying concept, adds K. Michael Pol-
lard, an associate professor at The Scripps 
Research Institute. “For every immunologist 
you’ll get one or two theories about what 
causes auto  immune disease,” he says. “That’s 
the state of the field—we’ve produced a lot 
of good work, but there are so many types of 
disease, and they all have mechanistic differ-
ences that might be subtle or they might be 
profound.”
In some cases, autoimmune illnesses 
occur when rogue proteins called autoan-
tibodies target cells and tissues instead of 
foreign invaders like viruses and bacteria. 
That’s what happens in Graves disease—
autoantibodies bind with hormone receptors 
on the thyroid gland. As a result, the organ 
becomes overactivated, leading to symptoms 
that include heat intolerance, unexplained 
weight loss, bulging eyeballs, hypertension, 
and tremor. Alternatively, T cells can target 
cells and tissues, Gilbert says, as occurs when 
they destroy insulin-producing islet cells in 
the pancreas, leading to type 1 diabetes. 
But even T cell–mediated illnesses can 
be accompanied by a proliferation of auto-
antibodies that can be detected in blood 
before symptoms manifest. For instance, cli-
nicians can assess autoimmune status among 
children thought to be at risk for type 1 
diabetes by measuring blood levels of auto-
antibodies against insulin and other antigens.
Rose  adds  that  some  autoimmune 
diseases share heritable components, such as 
variations in the gene that codes for human 
leukocyte antigen (HLA). HLA is the human 
version of a major gene family called the 
major histocompatibility complex (MHC), 
which plays crucial roles in immunity in ver-
tebrates. One MHC variation in particular, 
he says—known as the HLA-A1-B8-DR3 
haplotype—is implicated in several auto-
immune diseases. Indeed, most auto  immune 
illnesses can be tied to HLA variations of 
one kind or another, he adds. “So this tells 
me they’re fundamental to autoimmune dis-
ease etiology,” Rose says. 
Still, Rose acknowledges that although 
many gene variations are linked to auto-
immune diseases, each contributes just a 
small percentage to the overall risk. Dis-
ease occurs only when multiple genes act 
together, he says, and even then, genetics 
can’t explain the risk entirely, indicating that 
environmental factors are at play. “However, 
we have very little information about these 
factors,” Rose adds. “We need more data 
associating autoimmune illness with spe-
cific exposures. And we also need plausible 
biological mechanisms to explain how those 
exposures produce or exacerbate disease. 
This will dominate our research agenda over 
the course of the next decade.”
Environmental Links
According to Pollard, the best evidence 
linking  environmental  exposures  to 
auto  immune diseases so far comes from 
pharmaceutical drug studies. That’s not 
surprising, he says, given that patients in 
such studies are closely monitored with 
respect to dose, clinical outcome, and con-
founding from other factors. Two drugs in 
particular have been linked conclusively 
to SLE in a minority of patients, Pollard 
says: procainamide, a treatment for car-
diac arrhythmia, and hydralazine, used for 
high blood pressure.
9 “And when you take 
patients off the drugs, their lupus symp-
toms go away,” Pollard says.
Apart from pharmaceutical exposures 
and SLE, solid evidence also links gluten 
ingestion with celiac disease; indeed symp-
toms disappear upon gluten’s removal from 
the diet, according to Alessio Fasano, direc-
tor of the Center for Celiac Research at the 
University of Maryland School of Medi-
cine. However, human evidence for other 
environment–disease links is more tenuous, 
in part because of inherent limitations in 
environmental epidemiology, Pollard says: 
people tend to be mobile, they’re exposed 
to many environmental agents at once, and 
there’s often a significant time delay before 
the onset of autoimmune symptoms.
Proposed links also tend to suffer from 
conflicting study results. For instance, ciga-
rette smoking was linked to SLE in studies 
from the United Kingdom, Sweden, and 
Japan,
10,11,12 but three U.S.-based studies 
failed to show a similar connection.
13,14,15 
Sources interviewed for this story unani-
mously agree that rising prevalence rates are 
most evident in type 1 diabetes. Data from 
Finland, tracked by that country’s national 
health system, show type 1 diabetes rates 
more than doubled from 31 cases per 100,000 
people in 1980 to 64 cases per 100,000 
in 2005.
16 Increases were also detected in 
17 other European countries, at an average 
annual rise of 3.9% from 1989 to 2003.
17 The 
authors of that study predicted the number of 
new cases in children younger than 5 years in 
Europe will double by 2020 compared with 
2005, while the number of cases among those 
under age 15 will rise by 70%.
17 
Norris says increases in type 1 diabetes 
also have been documented in the United 
States through a program called SEARCH 
for Diabetes in Youth, which is coordinated 
by the U.S. Centers for Disease Control and 
Prevention.
18 SEARCH tracks incidence data 
gathered by registries in six states—Colorado, 
California, Hawaii, Ohio, South Carolina, 
and Washington. Norris says cases in Colo-
rado rose from 15 per 100,000 people in the 
1978–1988 time frame to 23.9 per 100,000 
between 2002 and 2004. “That’s about a 70% 
increase,” she says. “Not as big as what you’re 
seeing in Finland but substantial.” 
Diabetes: A Case in Point
What’s causing type 1 diabetes cases to 
rise? Terence Wilkin, a professor of endo-
crinology and metabolism at Peninsula Focus  | Environmental Factors in Autoimmune Disease
Medical School in Plymouth, UK, cites 
steady increases in childhood weight at 
decreasing ages. According to Wilkin, 
heavier body mass exacerbates insulin 
resistance, or the process by which insu-
lin becomes unable to coordinate glucose 
metabolism. That puts pancreatic beta cells 
into overdrive—as they struggle to meet 
insulin demands, the beta cells wear out, 
which initiates disease. “We consistently 
see that heavier children develop diabetes 
earlier in life,” Wilkin says. “And the link 
with insulin resistance explains why this is 
happening.” 
Norris says Wilkin’s hypothesis makes 
some intuitive sense. But citing prospec-
tive data
19 from the Diabetes Autoimmunity 
Study in the Young (DAISY), coordinated 
by the University of Colorado Denver, Nor-
ris says some children do show evidence of 
autoimmunity (measured by pancreatic islet 
cell autoantibodies in blood) before show-
ing signs of being heavier or larger than 
normal. “In our data there is no association 
between weight or body mass index and 
future appearance of autoimmunity,” she 
explains. “It could be that weight stress and 
insulin resistance follow the initiation of 
autoimmunity,” she adds. “So, I wouldn’t 
entirely discount Wilkin’s theory—we might 
just have to tweak it to fit the data.” 
Moreover, the DAISY cohort is limited 
to at-risk children identified by HLA type, 
Norris adds, whereas Wilkin’s hypothesis 
may apply to broader childhood popula-
tions that aren’t limited to genetically sus-
ceptible individuals. “And we haven’t tested 
Wilkin’s hypothesis in the general popula-
tion,” Norris says.
Meanwhile, some investigators have pro-
posed that type 1 diabetes might be related 
to consumption of infant formula, which 
became popular after World War II. Retro-
spective studies conducted mainly in Fin-
land and other countries took that view one 
step further, showing associations with cow’s 
milk specifically.
20 But more recent prospec-
tive investigations
21,22,23,24—which Norris 
says aren’t biased by the recall problems 
that sometimes characterize retro  spective 
designs—have been unable to confirm these 
associations. Instead, these studies have 
linked type 1 diabetes to other dietary expo-
sures in infants and young children, includ-
ing cereals with and without gluten, root 
vegetables, and fruit. 
“I’m not sure there’s any one factor in the 
infant diet that we can say is most important,” 
Norris says. “There’s too much variability in 
what the studies show; it might not be any 
one factor.” She says data also suggest type 1 
diabetes may be linked to entero  viruses
25 and 
to pollutants including nitrates and nitrate-
derived nitrosamines in drinking water.
26
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Brain
Eyes
Mouth
Spinal cord
Thyroid
Trachea
Heart
Lung
Esophagus
Joints
Stomach
Liver
Pancreas
Kidney
Large intestine
Small intestine
Bladder
Reproductive organs 
(male and female)
Blood and
blood vessels
Other sites:
 Skin
 Glands
 Muscles
 Nerves
Autoimmune  diseases  are  split  into  organ-specific  and  systemic  varieties.  Some 
sources cite as many as 120 distinct autoimmune diseases, which as a group are 
thought to affect 50 million Americans.
Body Parts Affected by  
Autoimmune 
DiseasesFocus  | Environmental Factors in Autoimmune Disease
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Other Exposures Provide 
Clues to Mechanisms of 
Autoimmunity
Industrial compounds and chemicals are 
linked to autoimmune disease mainly by 
occupational studies, in which exposures 
are more reliably ascertained from memory 
and workplace records than they are in 
studies of the general population. Some 
of the best supported associations, Miller 
says, link occupational exposure to crys-
talline silica with illnesses such as RA, 
SLE, and systemic sclerosis (also known as 
scleroderma), a disease of the connective 
tissues.
27,28,29
Jean Pfau, an associate professor of 
immuno  toxicology at Idaho State University, 
suggests that silica and asbestos—which has 
been associated with RA, SLE, and scleroder-
ma in miners and other residents in the former 
asbestos mining town of Libby, Montana
30—
evoke autoimmune disease in similar ways. 
Both compounds embed in the lungs, she 
says, which serves to attract immune cells and 
to produce inflammation. Moreover, silica 
and asbestos are cytotoxic, so they kill cells in 
ways that can generate a lot of cellular debris. 
What’s possible, Pfau says, is that B cells in 
the inflamed area might “lose tolerance” to 
self material—i.e., cell debris—and then go 
on to produce autoantibodies matched to that 
debris that target healthy cells throughout the 
body. Similar processes might be triggered 
by viral exposure, she says, for instance, to 
Epstein-Barr virus, which has been implicated 
in RA and SLE.
31
Also important in the immuno  toxicology 
literature is the solvent trichloroethylene 
(TCE), a ubiquitous groundwater con-
taminant. In a 2006 study by Gilbert and 
colleagues, TCE exposure altered the expres-
sion of T helper cells in mice, making them 
less susceptible to apoptosis (programmed 
cell death).
32 “ Apoptosis is supposed to pre-
vent autoreactive T helper cells—or more 
specifically, the CD4+ T cell subset that 
expresses CD4 protein on its surfaces—from 
expanding and causing autoimmune dis-
ease,” Gilbert explains. “And so suppressing 
this process can enhance vulnerability to a 
range of different illnesses.” 
Gilbert’s TCE-exposed mice showed 
evidence of immune activity in the liver—
including cytokine alterations and changes 
in lymphocyte gene expression—at nontoxic 
doses.
32 The mice eventually developed auto-
immune hepatitis, she says, but TCE’s effects 
on CD4+ T cells aren’t necessarily limited to 
liver disease.
Meanwhile, a number of studies also link 
solvents, including TCE, to autoimmune 
illnesses such as RA, SLE, and systemic 
sclerosis.
27 Whether those associations are 
real is difficult to tell, Gilbert says, because 
humans are typically exposed to chemical 
mixtures. 
Pollard says well-controlled human stud-
ies are a missing link in autoimmune disease 
research. “These illnesses are rare, and so you 
need large studies to detect associations, and 
that costs a lot of money,” he says. “We have 
all these bits and pieces—for instance, vari-
ous reports of people exposed in mines who 
have some features of autoimmune disease, 
but these people are also exposed to so much 
else. That’s the biggest problem: we need 
hard data on populations who are exposed 
and who are not exposed, and those studies 
aren’t easy to do.”
Needs for the Future
What’s needed most, Miller says, are bet-
ter data documenting the frequency and 
location of autoimmune diseases in the pop-
ulation. “We’re talking about a national reg-
istry, something that would allow us to get 
a handle on disease hot spots in relation to 
certain environmental exposures,” he says. 
“With that, we’d also be able to see how 
these illnesses are changing over time.” 
Miller points to the National Cancer 
Institute’s Surveillance Epidemiology and 
End Results (SEER) program
33 as an exam-
ple of a successful registry. SEER collects 
information on cancer incidence, prevalence, 
and survival from areas representing 28% 
of the U.S. population and compiles trend 
data for the entire country. “We don’t have 
anything like that for autoimmune disease,” 
Miller says. The consequence, he adds, is 
that whereas cancers are often addressed as 
a single entity, autoimmune illnesses are put 
in disease-specific silos, which prevents more 
efficient use of research dollars.
According to Rose, better diagnostics 
also are a major priority. Today, he says most 
people with autoimmune diseases aren’t 
diagnosed until it’s already late in the dis-
ease process. “We have good evidence that 
these illnesses can go on for years before they 
become clinically evident,” Rose says. “By 
the time we’re seeing these patients, a lot of 
damage has already occurred, and we’re left 
with the difficult job of trying to fix it. It 
would be better to find them earlier, so bet-
ter biomarkers that predict who’s at risk are 
an absolute necessity.” 
Charles W. Schmidt, MS, an award-winning science writer 
from Portland, ME, has written for Discover Magazine, Sci-
ence, and Nature Medicine. 
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